12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

unrelated transplant in first complete remission. J Clin Oncol, 22, 2816-2825.
Hunault M, Harousseau J-L, Delain M, Truchan-Graczyk M et al (2004). Better outcome of adult lymphoblastic
leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose
therapy and autologous BMT: a GOELAMS trial. Blood, 104, 3028-3037.
Ribera JM, Oriol A, Bethencourt C et al (2005). Comparison of intensive chemotherapy, allogeneic or autologous
stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic
leukemia. Results of the PETHEMA ALL-93 trial. Haematologica, 90, 1346-1356.
Yanada M, Matsuo K, Suzuki T, Naoe T (2006). Allogeneic hematopoietic stem cell transplantation as part of
postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a
metaanalysis. Cancer, 106, 2657-2663.
Goldstone AH, Richards SM, Lazarus HM, et al (2008). In adults with standard-risk acute lymphoblastic
leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete
remission, and an autologous transplantation is less effective than conventional consolidation/maintenance
chemotherapy in all patients: final results of the International ALL trial (MRC UKALL XII/ECOG E2993. Blood,
111. 1827-1833.
Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp
TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ. The outcome
of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults
with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
Blood. 2010 Jul 22;116(3):366-74. Epub 2010 Apr 19.
Mohty M, Labopin M, Volin L, Gratwohl A, Socié G, Esteve J, Tabrizi R, Nagler A, Rocha V.
Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for
patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and
Marrow Transplantation.
Blood. 2010 Aug 17. [Epub ahead of print]
Ph+ ALL, allo-HCT og imatinb
Avivi I, Goldstone AH (2003). Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplantation, 31,
623-632.
Yanada M, Takeuchi J, Sugiura I et al (2006). High complete remission rate and promising outcome by
combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblasic leukemia:
a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24, 460-466.
Wassmann B, Pfeifer H, Goekbuget N et al (2006). Alternating versus concurrent schedules of imatinib and
chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood,
108, 1469-1477.
21